Inhibition of human aldehyde oxidase activity by diet-derived constituents: Structural influence, enzyme-ligand interactions, and clinical relevance

Drug Metabolism and Disposition

Volumn 43, Issue 1, 2015, Pages 34-41

  Barr, John T ^a   Jones, Jeffrey P ^b   Oberlies, Nicholas H ^c   Paine, Mary F ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

^c UNIVERSITY OF NORTH CAROLINA AT GREENSBORO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 O BENZYLGUANINE; 6',7' DIHYDROXYBERGAMOTIN; ALDEHYDE OXIDASE; APIGENIN; AURANTIIN; EPICATECHIN; EPICATECHIN GALLATE; EPIGALLOCATECHIN; EPIGALLOCATECHIN GALLATE; HERBACEOUS AGENT; HESPERIDIN; HYMECROMONE; HYMECROMONE GLUCURONIDE; ISOSILYBIN A; ISOSILYBIN B; ISOSILYCHRISTIN; KAEMPFEROL; NARINGENIN; PSORALEN; QUERCETIN; RESVERATROL; SILICRISTIN; SILIDIANIN; SILYBIN A; SILYBIN B; TANGERETIN; TAXIFOLIN; UNCLASSIFIED DRUG; CATECHIN; CYTOCHROME P450; ENZYME INHIBITOR; GUANINE; LIGAND; O(6)-BENZYLGUANINE; TEA; XENOBIOTIC AGENT;

ARTICLE; COMPETITIVE INHIBITION; COMPUTER MODEL; CONTROLLED STUDY; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; FEMALE; HUMAN; HUMAN CELL; IC50; LIVER CYTOSOL; MALE; MOLECULAR DOCKING; MOLECULAR MODEL; PREDICTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; DIET; FOOD DRUG INTERACTION; METABOLISM; OXIDATION REDUCTION REACTION; PHYSIOLOGY; TEA;

ALDEHYDE OXIDASE; CATECHIN; CYTOCHROME P-450 ENZYME SYSTEM; DIET; ENZYME INHIBITORS; FOOD-DRUG INTERACTIONS; GUANINE; HUMANS; LIGANDS; OXIDATION-REDUCTION; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; TEA; XENOBIOTICS;

EID: 84919682610     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.061192     Document Type: Article

References (43)

1. Bailey DG, Malcolm J, Arnold O, and Spence JD (1998) Grapefruit juice-drug interactions. Br J Clin Pharmacol 46:101-110.
2. Barr JT, Choughule K, and Jones JP (2014) Enzyme kinetics, inhibition, and regioselectivity of aldehyde oxidase. Methods Mol Biol 1113:167-186.
3. Barr JT and Jones JP (2011) Inhibition of human liver aldehyde oxidase: implications for potential drug-drug interactions. Drug Metab Dispos 39:2381-2386.
4. Barr JT and Jones JP (2013) Evidence for substrate-dependent inhibition profiles for human liver aldehyde oxidase. Drug Metab Dispos 41:24-29.
5. Boocock DJ, Faust GE, Patel KR, Schinas AM, Brown VA, Ducharme MP, Booth TD, Crowell JA, Perloff M, and Gescher AJ, et al. (2007) Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 16:1246-1252.
6. Brantley SJ, Graf TN, Oberlies NH, and Paine MF (2013) A systematic approach to evaluate herb-drug interaction mechanisms: investigation of milk thistle extracts and eight isolated constituents as CYP3A inhibitors. Drug Metab Dispos 41:1662-1670.
7. Brantley SJ, Argikar AA, Lin YS, Nagar S, and Paine MF (2014a) Herb-drug interactions: challenges and opportunities for improved predictions. Drug Metab Dispos 42:301-317.
8. Brantley SJ, Gufford BT, Dua R, Fediuk DJ, Graf TN, Scarlett YV, Frederick KS, Fisher MB, Oberlies NH, and Paine MF (2014b) Physiologically based pharmacokinetic modeling framework for quantitative prediction of an herb-drug interaction. CPT Pharmacometrics Syst Pharmacol 3:e107.
9. Cao H, Pauff JM, and Hille R (2014) X-ray crystal structure of a xanthine oxidase complex with the flavonoid inhibitor quercetin. J Nat Prod 77:1693-1699.
10. Choughule KV, Barr JT, and Jones JP (2013) Evaluation of rhesus monkey and guinea pig hepatic cytosol fractions as models for human aldehyde oxidase. Drug Metab Dispos 41: 1852-1858.
11. Chow HH, Cai Y, Alberts DS, Hakim I, Dorr R, Shahi F, Crowell JA, Yang CS, and Hara Y (2001) Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E. Cancer Epidemiol Biomarkers Prev 10 :53-58.
12. Coelho C, Mahro M, Trincão J, Carvalho AT, Ramos MJ, Terao M, Garattini E, Leimkühler S, and Romão MJ (2012) The first mammalian aldehyde oxidase crystal structure: insights into substrate specificity. J Biol Chem 287:40690-40702.
13. Cook PF and Cleland WW (2007) Enzyme Kinetics and Mechanism, Garland Science, New York.
14. Dalvie D, Sun H, Xiang C, Hu Q, Jiang Y, and Kang P (2012) Effect of structural variation on aldehyde oxidase-catalyzed oxidation of zoniporide. Drug Metab Dispos 40 : 1575-1587.
15. Dastmalchi S and Hamzeh-Mivehrod M (2005) Molecular modelling of human aldehyde oxidase and identification of the key interactions in the enzyme-substrate complex. DARU J Pharm Sci 13:82-93.
16. Dürr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, and Fattinger K (2000) St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 68:598-604.
17. Garattini E and Terao M (2012) The role of aldehyde oxidase in drug metabolism. Expert Opin Drug Metab Toxicol 8:487-503.
18. Gardiner P, Graham RE, Legedza AT, Eisenberg DM, and Phillips RS (2006) Factors associated with dietary supplement use among prescription medication users. Arch Intern Med 166: 1968-1974.
19. Graf TN, Wani MC, Agarwal R, Kroll DJ, and Oberlies NH (2007) Gram-scale purification of flavonolignan diastereoisomers from Silybum marianum (Milk Thistle) extract in support of preclinical in vivo studies for prostate cancer chemoprevention. Planta Med 73: 1495-1501.
20. Gufford BT, Chen G, Lazarus P, Graf TN, Oberlies NH, and Paine MF (2014) Identification of diet-derived constituents as potent inhibitors of intestinal glucuronidation. Drug Metab Dispos 42:1675-1683.
21. Hamzeh-Mivehroud M, Rahmani S, Rashidi MR, Hosseinpour Feizi MA, and Dastmalchi S (2013) Structure-based investigation of rat aldehyde oxidase inhibition by flavonoids. Xenobiotica 43:661-670.
22. Hamzeh-Mivehroud M, Rahmani S, Feizi MA, Dastmalchi S, and Rashidi MR (2014) In vitro and in silico studies to explore structural features of flavonoids for aldehyde oxidase inhibition. Arch Pharm (Weinheim) 347:738-747.
23. Hutzler JM, Obach RS, Dalvie D, and Zientek MA (2013) Strategies for a comprehensive understanding of metabolism by aldehyde oxidase. Expert Opin Drug Metab Toxicol 9: 153-168.
24. Inoue K, Mizuo H, Kawaguchi S, Fukuda K, Kusano K, and Yoshimura T (2014) Oxidative metabolic pathway of lenvatinib mediated by aldehyde oxidase. Drug Metab Dispos 42: 1326-1333.
25. Köck K, Xie Y, Hawke RL, Oberlies NH, and Brouwer KL (2013) Interaction of silymarin flavonolignans with organic anion-transporting polypeptides. Drug Metab Dispos 41: 958-965.
26. Li L, Hu H, Xu S, Zhou Q, and Zeng S (2012) Roles of UDP-glucuronosyltransferases in phytochemical metabolism of herbal medicines and the associated herb-drug interactions. Curr Drug Metab 13:615-623.
27. Misaka S, Yatabe J, Müller F, Takano K, Kawabe K, Glaeser H, Yatabe MS, Onoue S, Werba JP, and Watanabe H, et al. (2014) Green tea ingestion greatly reduces plasma concentrations of nadolol in healthy subjects. Clin Pharmacol Ther 95:432-438.
28. Mohamed ME and Frye RF (2011) Effects of herbal supplements on drug glucuronidation. Review of clinical, animal, and in vitro studies. Planta Med 77:311-321.
29. Napolitano JG, Lankin DC, Graf TN, Friesen JB, Chen SN, McAlpine JB, Oberlies NH, and Pauli GF (2013) HiFSA fingerprinting applied to isomers with near-identical NMR spectra: the silybin/isosilybin case. J Org Chem 78:2827-2839.
30. Obach RS (2004) Potent inhibition of human liver aldehyde oxidase by raloxifene. Drug Metab Dispos 32:89-97.
31. Obach RS, Huynh P, Allen MC, and Beedham C (2004) Human liver aldehyde oxidase: inhibition by 239 drugs. J Clin Pharmacol 44:7-19.
32. Paine MF, Criss AB, and Watkins PB (2004) Two major grapefruit juice components differ in intestinal CYP3A4 inhibition kinetic and binding properties. Drug Metab Dispos 32: 1146-1153.
33. Pryde DC, Dalvie D, Hu Q, Jones P, Obach RS, and Tran TD (2010) Aldehyde oxidase: an enzyme of emerging importance in drug discovery. J Med Chem 53:8441-8460.
34. Jin FRobeson M, Zhou H, Moyer C, and Ramanathan S (2013) Pharmacokinetics and safety of idelalisib, a novel PI3K d inhibitor, In Japanese and Caucasian subjects. Blood 122: 5575-5575.
35. Roth M, Timmermann BN, and Hagenbuch B (2011) Interactions of green tea catechins with organic anion-transporting polypeptides. Drug Metab Dispos 39:920-926.
36. Sahi J, Khan KK, and Black CB (2008) Aldehyde oxidase activity and inhibition in hepatocytes and cytosolic fractions from mouse, rat, monkey and human. Drug Metab Lett 2: 176-183.
37. Tayama Y, Sugihara K, Sanoh S, Miyake K, Morita S, Kitamura S, and Ohta S (2011) Effect of tea beverages on aldehyde oxidase activity. Drug Metab Pharmacokinet 26: 94-101.
38. Tucker GT, Houston JB, and Huang SM (2001) Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus. Pharm Res 18:1071-1080.
39. Wang L and Morris ME (2005) Liquid chromatography-tandem mass spectroscopy assay for quercetin and conjugated quercetin metabolites in human plasma and urine. J Chromatogr B Analyt Technol Biomed Life Sci 821:194-201.
40. Wen Z, Dumas TE, Schrieber SJ, Hawke RL, Fried MW, and Smith PC (2008) Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract. Drug Metab Dispos 36: 65-72.
41. Zhou S, Chan E, Li SC, Huang M, Chen X, Li X, Zhang Q, and Paxton JW (2004) Predicting pharmacokinetic herb-drug interactions. Drug Metabol Drug Interact 20: 143-158.
42. Zhu HJ, Brinda BJ, Chavin KD, Bernstein HJ, Patrick KS, and Markowitz JS (2013) An assessment of pharmacokinetics and antioxidant activity of free silymarin flavonolignans in healthy volunteers: a dose escalation study. Drug Metab Dispos 41:1679-1685.
43. Zientek M, Jiang Y, Youdim K, and Obach RS (2010) In vitro-in vivo correlation for intrinsic clearance for drugs metabolized by human aldehyde oxidase. Drug Metab Dispos 38:1322-1327.